Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph + leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small fraction of patients. Thus, etiology of the lymphocytosis still remains unclear. Here, we identified NK cells as the dominant LGLs expanding in dasatinib-treated patients, and applied principal component analysis (PCA) to an extensive panel of NK cell markers to explore underlying factors in NK cell activation. PCA displayed phenotypic divergence of NK cells that reflects CMV-associated differentiation and genetic differences, and the divergence was markedly augmented in CMV-seropositive dasatinib-treated patients. Notably, the CMV-associated highly differentiated status of NK cells was already observed at leukemia diagnosis, and was further enhanced after starting dasatinib in virtually all CMV-seropositive patients. Thus, the extensive characterization of NK cells by PCA strongly suggests that CMV is an essential factor in the NK cell activation, which progresses stepwise during leukemia and subsequent dasatinib treatment most likely by subclinical CMV reactivation. This study provides a rationale for the exploitation of CMV-associated NK cell activation for treatment of leukemias.
INTRODUCTION
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 kinase have revolutionized the treatment strategy for Philadelphia chromosomepositive (Ph + ) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Among the TKIs, dasatinib causes a unique immunological phenomenon, that is, an increase in the number of cytotoxic lymphocytes, morphologically large granular lymphocytes (LGLs), in a substantial proportion of Ph + leukemia patients. 1, 2 It has been reported that the LGL lymphocytosis is due to an expansion of clonal CD8 + T cells or natural killer (NK) cells. 3 Importantly, LGL lymphocytosis during dasatinib treatment is associated with superior therapeutic responses. 1, 2 Thus, investigating the mechanisms underlying the LGL lymphocytosis shall be instrumental in improving the treatment outcome for Ph + leukemia. In addition to the BCR-ABL1 kinase, dasatinib inhibits a broad spectrum of tyrosine kinases, including key regulators of immune responses. 4 In agreement with this profile, in vitro studies have shown immunosuppressive effects of dasatinib on various immune cells, such as T cells, 5, 6 NK cells, 7 and plasmacytoid dendritic cells. 8 However, these observations are apparently inconsistent with the in vivo expansion of LGLs in dasatinib-treated patients, suggesting that the expansion is not mediated by a direct effect of dasatinib on T cells and NK cells. A previous study implicated cytomegalovirus (CMV) in the dasatinib-related LGL expansion, since it is predominantly observed in CMV-seropositive (CMV + ) patients. 9 However, CMV reactivation is reported only in a small fraction of patients, 9, 10 and therefore, underlying factors in the lymphocytosis have been still uncertain.
We hypothesized that detailed phenotypic profiling of LGLs should provide important clues to elucidate the overall mechanism of the LGL lymphocytosis. As CD8 + T cells and NK cells, in particular the latter, express a complex mosaic of inhibitory and activating receptors with large variations among individuals, 11 multiparametric phenotyping is required to assess the accurate status of these cells. Principal component analysis (PCA) is a suitable method to integrate such complex datasets. PCA is a mathematical algorithm that reduces dimensionality of multiparametric data by identifying unspecified factors (principal components) behind the dataset. 12 PCA has been used to analyze phenotypic diversity of CD8 + T cells, 13 gene expression profiles of T cells and NK cells, 14 and receptor expression patterns of NK cells. 15 In this study, we aimed to obtain a complete picture of the expanding LGLs in dasatinib-treated patients and thereby gain insights into underlying mechanisms of the LGL expansion. We first identified NK cells as the dominant LGLs, and then extensively performed multiparametric phenotyping of NK cells. By adopting PCA as the analytical measure, we succeeded in obtaining precise pictures of the NK cell status in leukemia patients, and uncovered critical roles of CMV, leukemia, and dasatinib in NK cell expansion and differentiation.
MATERIALS AND METHODS

Patients and samples
Written informed consent was obtained from all patients and healthy donors. The study was conducted in accord with the principles of Helsinki Declaration and was approved by the Kyoto University Hospital Ethics Committee.
The study population was dasatinib-treated (DA) CML or Ph + ALL patients (n = 36), other TKI (imatinib or nilotinib)-treated (OTKI) patients (n = 26), and healthy donors (HDs) (n = 15). The patients and donors were divided into 5 groups according to the TKIs used and CMV serology (Supplementary Table 1 ). The OTKI patients were all CMV + . Among the 36 DA patients, dasatinib was the first-line therapy in 29 patients. Both diagnostic-phase and follow-up samples were obtained from 25 CML patients (20 DA patients, 5 OTKI patients).
LGL lymphocytosis was defined as an increased absolute count of lymphocytes above the mean of the HDs plus 2 standard deviation (s.d.), with LGL morphology (430% peripheral blood lymphocytes) observed on more than 2 occasions after 41 month of therapy. Blood sampling schedules are described in Supplementary Methods.
Immunophenotyping of lymphocytes
Most of the analyzed samples were non-frozen. Cell staining was performed with appropriate combinations of antibodies. The antibodies used and the method of data analysis are described in Supplementary Methods.
PCA
We conducted PCA with a covariance matrix of expression percentages for 19 phenotypic markers on NK cells from 77 individuals to deal with the absolute variation (Supplementary Table 2 ). The PCA was performed using princomp function in R software 3.1.3 (The R Foundation for Statistical Computing, Vienna, Austria). The component loadings were calculated as correlation between measured expression values and principal component scores. The PCA scores of each NK cell profile from the diagnostic-phase and the follow-up samples were predicted based on eigenvectors in the first PCA and were superimposed on the PCA result.
Polyfunctionality assays
Assays were performed by co-culture of NK cells with target cells, and several markers of NK cell functionality were simultaneously detected. Detailed methods are described in Supplementary Methods.
Statistical analysis
The data of lymphocyte count and NK cell marker expression were compared between the CMV + DA group and the other groups by the Wilcoxon rank sum test and were adjusted by the Holm's method. For multiple comparison of principal component values, the procedures are described in each figure legends. Statistical significance was defined as Po0.05 with a two-tailed test. All statistics analyses were performed using the R software.
RESULTS
The number of NK cells increase in CMV
+ DA patients
The characteristics of the 36 DA patients are summarized in Table 1 . Among them, 19 developed LGL lymphocytosis: 13 were NK cells, 2 were T cells, and 4 were both NK and T cells.
LGL lymphocytosis was observed only in CMV + patients, and 7 of the 30 CMV + patients developed CMV reactivation as defined by an elevation of CMV-IgM or a positive result of PCR, while undergoing dasatinib treatment. Two patients developed CMV reactivation without LGL lymphocytosis.
Next we compared the numbers of NK cells and T-cell subsets in blood among DA patients, OTKI patients, and HDs ( Figure 1a) Figure 2) , and then to integrate the whole dataset, we performed PCA (Figure 2 ). The first 2 principal components designated by PCA (Figure 2a ) accounted for more than half of the variation (principal component 1 [PC1] 39.6%, PC2 13.2%). When PC1 and PC2 were plotted on a two dimensional plane, they displayed a triangular hierarchical structure (Figure 2b ) schematically depicted in Figure 2c ; the increase in PC1 values synchronized with divergence of PC2 values. Furthermore, the study cohorts can be classified into 4 layers (Figure 2c ). That is, layers of CMV -group, CMV + HD, CMV + OTKI, and CMV + DA showed significant stepwise increases in PC1 values, accompanied by increases in PC2 divergence (Figure 2b-d) .
PCA algorithm defined PC1 to be composed mainly of positive loadings of NKG2C, CD57, and LIR-1, and of negative loadings of NKp30 and NKp46 (Figure 2a) . In other words, PC1 correlated positively with expression levels of the former, and negatively with those of the latter (Supplementary Figure 3) . The pattern of these markers indicates that the higher PC1 value is associated with the greater degree of CMV-driven differentiation. 16, 19, 20 This is also supported by the fact that CMV − individuals had the least PC1 values (Figure 2b Taken together, our results revealed PCA as a powerful tool to capture the nature of NK cell changes: the stepwise differentiation (PC1) and phenotypic diversification (PC2) associated with CMV infection and further with dasatinib treatment.
As previous studies have reported an increase in CD8 + T cells in CMV + DA patients, 2,9,10 and CD8 + T cells share the activating and inhibitory receptors with NK cells, 11, 25, 26 we also conducted PCA for Dasatinib treatment enhances higher CMV-associated differentiated status in patients previously treated with imatinib or nilotinib To confirm the unique potential of dasatinib to induce higher differentiated status of NK cells, we conducted a longitudinal examination of NK cells in patients who had been treated with imatinib or nilotinib, and then switched to dasatinib after achieving a major molecular response (MMR). We examined the phenotype and the number of NK cells in 6 CMV + patients (Supplementary Figure 6) , and applied PCA (Figure 3a) . Whereas it is difficult to recognize continuously ongoing NK cell differentiation during dasatinib treatment by separate presentation of individual markers (Supplementary Figure 6) , the PCA revealed progressive changes of NK cells toward enhanced CMV-associated differentiation (increases in PC1 values) throughout dasatinib treatment in 5 of the 6 patients ( Figure 3a ). This again illustrates that PCA is a useful method for visualizing the overall differentiation status of NK cells. Intriguingly, whereas the 5 patients who exhibited enhanced NK cell differentiation also developed NK cell expansion after switching to dasatinib (Figure 3b) , there was one exceptional patient whose PC1 value hardly increased during the observation and developed no NK cell expansion (marked with asterisks in Figure 3a and b) . This correlation suggests the tight relationship between differentiation and expansion of NK cells. 
CMV-driven NK cells in dasatinib-treated patients K-i Ishiyama et al
Detailed data were obtained from a Ph + ALL patient, who had achieved a hematological remission with chemotherapy and imatinib, and then switched to dasatinib as maintenance therapy (Figure 3c ). She developed persistent, asymptomatic CMV viremia after starting dasatinib, accompanied by an expansion and differentiation of NK cells but not CD8 + T cells (Figure 3a , marked with an arrow and Figure 3c) .
Taken together, these data demonstrate that dasatinib induces further differentiation and expansion of NK cells in CMV + leukemia patients after switch from imatinib or nilotinib, indicating the distinctive immunomodulatory effect of dasatinib.
Enhanced NK cell differentiation was observed in CMV + CML patients at diagnosis and was further augmented by dasatinib Next, to observe the effect of dasatinib on NK cells from the time of leukemia diagnosis, NK cell phenotypes at diagnosis and at later time points were examined in 25 CML patients (20 CMV + and 5 CMV − patients). Unexpectedly, while CMV − CML patients at diagnosis (CMV − CML group) showed no significant difference with CMV − HDs, CMV + CML patients at diagnosis (CMV + CML group) had NK cells with a greater degree of differentiation compared to CMV + HDs (Figure 4a and c) . CMV-IgM titer was elevated in 6 CMV + patients, and CMV DNA was detected in 5 CMV + patients at CML diagnosis (data not shown). After starting dasatinib, the NK cell profiles shifted to further differentiated status in all the CMV + DA patients, whereas the shift was minimal in CMV + OTKI patients and in CMV − DA patients (Figure 4a ). These data suggest that the mere onset of CML accompanied CMV reactivation, leading to the enhanced NK cell differentiation. This CMV-associated NK cell differentiation was further enhanced with dasatinib treatment, but not with other TKIs.
Similarly, in newly diagnosed acute myeloid leukemia (AML) (Supplementary Table 3 patients (Figure 4c ). These classified groups indicate that NK cell differentiation triggered by CMV was enhanced by the occurrence of leukemia, and then one step further by dasatinib treatment.
Highly differentiated status of NK cells at diagnosis predicts robust expansion after starting dasatinib Although the majority of CMV + CML patients at diagnosis had NK cells with an enhanced degree of differentiation (PC1 ⩾ 0), several patients exhibited relatively low levels of differentiation (PC1 o 0) (Figure 4a ). To examine whether NK cells with such different degrees of differentiation at diagnosis behave differently after starting dasatinib, we examined phenotypes and numbers of NK cells longitudinally.
As depicted in Figure 4a and described in detail in Figure 5a and b, PC1 values in CMV + patients constantly increased at similar rates irrespective of the initial PC1 values (PC1 ⩾ 0 or o0), whereas there was no increase in CMV -patients (Figure 5a ). These data indicate that dasatinib treatment enhances the CMV-associated NK cell differentiation in virtually all CMV + patients. Interestingly, the patients with higher initial PC1 values (PC1 ⩾ 0) showed significantly greater NK cell expansion after starting dasatinib than those with lower initial PC1 values (PC1 o0) (Figure 5c and d) . These data indicate that pretreatment differentiated status of NK cells as defined by PCA predicts robust expansion of NK cells after starting dasatinib in CMV + patients. In addition, the patients with higher initial PC1 values exhibited significantly greater decreases in BCR-ABL1 mRNA (MMR in 5 of 9 patients) at 3 months after starting dasatinib than those with lower initial PC1 values (MMR in 0 of 6 patients) (P = 0.043 by Fisher's exact test), suggesting rapid and deeper responses accompanying NK cell expansion.
Polyfunctional NKG2C
+ NK cells with high cytotoxic activity against leukemic cells expand in the CMV + DA patients
To examine the effect of TKIs on the function of CMV-associated NK cells in vivo, we performed polyfunctionality assays using the CML-derived K562 cell line as a target. The degranulation marker CD107a was used to evaluate cytotoxic function, and IFN-γ or TNF-α release for cytokine productions. The percentages of responsive CD56 dim NK cells were similar among the DA, OTKI, and HD groups (Supplementary Figure 7a) . When the CD56 dim NK cells were divided into NKG2C + and NKG2C -populations, the former contained higher frequencies of cytotoxic and cytokine-producing polyfunctional cells than the latter in DA patients, but not in OTKI patients or HDs (Supplementary Figure 7b) . In contrast, CD56 dim NK cells (Supplementary Figure 8a) , especially NKG2C + population ( Supplementary Figure 8b) , showed hyporesponsiveness to exogenous cytokines in DA patients. Expansion of such CMV À associated, target cell-responsive but cytokine-unresponsive NKG2C + NK cells is consistent with a previous report. 27 Together with the highest expression of granzyme B in NK cells from CMV + DA patients (Supplementary Figure 2) , these data indicate that dasatinib treatment promotes expansion of polyfunctional NKG2C + NK cells with high cytotoxic activity.
DISCUSSION
In this study, we identified NK cells as the dominantly expanding
LGLs in CMV + DA patients. Then we conducted a multiparametric analysis of NK cells and visualized the data using PCA. Remarkably, the PCA revealed that virtually all the CMV + patients exhibited enhancement of CMV-associated NK cell differentiation during dasatinib treatment, regardless of the presence or absence of documented CMV reactivation. Furthermore, similar enhancement was observed with mere presence of leukemia, exclusively again in CMV + patients. Based on these comprehensive analyses, we propose CMV as an indispensable factor followed by leukemia and dasatinib as enhancing factors in the NK cell activation.
As shown in Table 1 and Figure 1 , the majority of expanding LGLs in DA patients were NK cells, and T-cell expansion was relatively rare. This was different from the previous reports, where increases in the numbers of γδ T cells and CD8 + T cells were more frequently observed. 2, 9, 10 This discrepancy might be due to difference in timing of blood sampling from that in the previous studies; samples were collected at least 6 h after administration of dasatinib to avoid the influence of the rapid mobilization of lymphocytes induced by dasatinib (Supplementary Methods). 28, 29 Association of CMV with the development of NK cell expansion during dasatinib treatment has been reported in a previous study, 9 but to what extent CMV is involved was unclear since CMV reactivation was reported only in part of the patients who experienced NK cell expansion.
9,10 Consistently, we detected CMV reactivation only in part of the CMV + DA patients (Table 1) . It has been reported that acute infection of hantavirus 30 or chikungunya virus 31 induces transient expansion of NKG2C + NK cells in CMV + individuals. Thus, it is possible that infection or reactivation of viruses other than CMV was responsible for the NK cell expansion after dasatinib treatment. However, it is more likely that CMV assays were not sufficiently sensitive to detect a low level of CMV reactivation, since the NK cell differentiation was observed only in CMV + patients and such phenotype chronically and constantly enhanced after starting dasatinib in virtually all the CMV + patients (Figures 2-5 ). Thus, we assume that a low level of continuous CMV reactivation, as exemplified in Figure 3c , underlay the NK cell expansion and differentiation during dasatinib treatment.
It has been reported that dasatinib suppresses T-cell receptormediated signal transduction through inhibiting Lck. 32 Dasatinib also suppresses NK cell activity by inhibiting proximal signaling events leading to decreased phosphorylation of extracellular regulated kinases 1/2 and phosphatidylinositol 3-kinase. 33 Thus, it is likely that the NK cell expansion and differentiation are not a direct effect of dasatinib but indirectly occur by suppression of T-cell and NK cell activity and resultant CMV reactivation.
We presented 3 data of PCA: cross-sectional (Figure 2b ), longitudinal (Figure 3a) , and pretreatment analyses (Figure 4a) . Notably, the cross-sectional analysis showed stepwise CMV-associated NK cell activation as shown by increment of differentiation (PC1) and phenotypic diversification (PC2) (Figure 2b-d) . The longitudinal analysis revealed steady enhancement of NK cell differentiation after switching from imatinib or nilotinib to dasatinib (Figure 3a) . Intriguingly, the pretreatment analysis revealed that the majority of CMV + CML patients already had more differentiated NK cells even at diagnosis of leukemia compared to CMV + HDs (Figure 4a  and c) , accompanied by detectable CMV reactivation in part of the patients. Such enhanced NK cell differentiation at diagnosis was also observed in CMV + AML patients (Figure 4b and c) . It has been reported that a substantial proportion of patients with hematological malignancies have detectable levels of CMV DNA in blood. 34 Thus, we presume that the onset of leukemia elicits CMV reactivation and consequent NK cell activation, and that subsequent dasatinib treatment induces further CMV reactivation, leading to CMV-associated strong NK cell differentiation and expansion in CMV + DA patients. Given the improved clinical outcome in patients who experienced LGL expansion, 1,2 it may be beneficial to predict NK cell expansion before starting dasatinib. We found that whereas enhancement of NK cell differentiation steadily occurred during dasatinib treatment irrespective of the degree of differentiation at diagnosis (Figure 5a and b) , robust expansion of NK cells was observed only in the patients with higher degrees of differentiation at diagnosis (Figure 5c and d) . In addition, the NK cell differentiation at diagnosis correlated with frequent achievement of MMR at 3 months. Thus, the degree of NK cell differentiation at diagnosis serves as a predictive factor for robust expansion of NK cells and possibly for an earlier clinical response. Importantly, as the molecular response at 3 months accurately predicts the long-term outcome of TKI therapies, 35 the degree of CMVassociated NK cell differentiation at diagnosis might ultimately predict the final outcome of dasatinib treatment.
Notably, the CMV-associated NKG2C + NK cells has been considered to represent the human counterpart of mouse memory NK cells, 36 and have distinctive molecular signature by epigenetic modification. 37, 38 It is possible that the prompt expansion of NK cells with higher degrees of differentiation after starting dasatinib may reflect the property of immunological memory. Since such adaptive NK cells also appear to reduce relapse of hematological malignancies in allogeneic transplant patients who experienced CMV reactivation, 38 the CMV-associated distinctive type of adaptive NK cells may contribute to suppressing leukemia relapse in transplant patients as well as in dasatinib-treated patients.
An important issue in CML treatment is whether TKIs can be discontinued after achieving a deep molecular response. A substantial proportion of such patients maintains the response for more than 12 months after discontinuation of imatinib 39 or dasatinib. 40 Notably, increases in NK cells 40, 41 but not T cells 40 associate with longer treatment-free remission, implying that immunological surveillance by NK cells is involved in keeping CML under control. Thus, the CMV-associated NK cell activation may contribute to preventing CML relapse after discontinuing dasatinib.
There are several possible mechanisms by which the expanded adaptive NK cells exert anti-leukemia effects. For example, polyfunctional NKG2C + NK cells with high cytotoxic activity (Supplementary Figure 7b) may kill leukemic cells directly by recognizing NKG2D ligands 42 or may enhance antitumor immunity indirectly by activating dendritic cells. 43 Elucidation of the exact mechanisms needs further study. (d) NK cell counts after starting dasatinib between the two groups were compared by Welch's t-test. Dark gray box: high group, light gray box: low group. *P o0.05, **P o0.01.
In conclusion, this study using PCA suggests that the distinctive NK cell subset, that is, CMV-associated adaptive NK cells, is responsible for the dasatinib-induced NK cell expansion, which likely occurs through subclinical CMV reactivation. Intriguingly, the CMV-associated highly differentiated status is already observed at leukemia diagnosis in a large proportion of patients, and predicts prompt expansion of NK cells after starting dasatinib. These findings provide a rationale for the exploitation of CMV-associated NK cell activation to improve the treatment outcome for Ph + leukemia. Furthermore, the findings may illustrate exploitation of immunity against resident viruses, virobiota, for the control of malignancies. 44 
